Paradigm Biocapital Advisors Lp

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$4.89B
Q ending 2026-03-31
Prior quarter
$3.92B
Q ending 2025-12-31
Change
+24.9% QoQ · +124.2% YoY
Positions
35
reported holdings

Largest positions

All 35 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
Arcellx IncACLXShares$663.0M5.8M
Revolution Medicines IncRVMDShares$647.3M6.7M
Nuvalent Inc5AXShares$545.5M5.3M
Vaxcyte IncPCVXShares$278.5M4.8M
Edgewise Therapeutics IncEWTXShares$232.0M7.4M
Genmab A/SGMABShares$213.8M8.0M
Insmed IncINSMShares$205.1M1.3M
Tarsus Pharmaceuticals IncTARSShares$179.7M2.6M
Belite Bio IncBLTEShares$177.7M1.1M
Erasca IncERASShares$168.2M10.4M
Centessa Pharmaceuticals Plc260Shares$142.0M3.6M
Olema Pharmaceuticals IncOLMAShares$119.6M8.0M
Terns Pharmaceuticals Inc430Shares$116.9M2.2M
Oruka Therapeutics IncORKAShares$113.8M2.3M
Apogee Therapeutics IncAPGEShares$113.5M1.3M
Spyre Therapeutics IncSYREShares$98.7M2.0M
Cytokinetics IncCYTKShares$97.6M1.5M
Abivax SaABVXShares$86.0M772K
Tango Therapeutics IncTNGXShares$83.9M4.0M
Maze Therapeutics IncMAZEShares$81.9M2.7M
Tyra Biosciences IncTYRAShares$78.7M2.1M
Viridian Therapeutics IncVRDNShares$61.6M3.1M
Scholar Rock Hldg CorpSRRKShares$60.3M1.2M
Mirum Pharmaceuticals IncMIRMShares$57.7M625K
Eyepoint IncEYPTShares$40.5M3.1M
Lexeo Therapeutics IncLXEOShares$35.5M6.2M
Veradermics IncMANEShares$33.2M525K
Vor Biopharma IncVORShares$31.2M1.8M
Urogen Pharma LtdShares$30.6M1.7M
Structure Therapeutics IncGPCRShares$26.3M545K
Inventiva SaIVAShares$22.2M4.0M
Oric Pharmaceuticals IncORICShares$21.6M1.7M
Assembly Biosciences IncASMBShares$18.5M665K
Bridgebio Oncology TherapeutBBOTShares$7.8M868K
Kalaris Therapeutics IncKLRSShares$4.0M700K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.